Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiaoning Bi, Jiandong Sun, Angela X. Ji & Michel Baudry. (2016) Potential therapeutic approaches for Angelman syndrome. Expert Opinion on Therapeutic Targets 20:5, pages 601-613.
Read now
Read now
Daniele Mattei, Regina Schweibold & Susanne A Wolf. (2015) Brain in flames – animal models of psychosis: utility and limitations. Neuropsychiatric Disease and Treatment 11, pages 1313-1329.
Read now
Read now
Articles from other publishers (30)
Santiago Ballaz & Michel Bourin. 2023. Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders. Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders
459
486
.
Benneth Ben-Azu, Olusegun G. Adebayo, Thiophilus Aghogho Jarikre, Mega O. Oyovwi, Kesiena Emmanuel Edje, Itivere Adrian Omogbiya, Anthony T. Eduviere, Emuesiri Goodies Moke, Bienose S. Chijioke, Onyebuchi S. Odili, Osemudiame P. Omondiabge, Aghogho Oyovbaire, Daniel T. Esuku, Esther O. Ozah & Kelvin Japhet. (2022) Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice. Metabolic Brain Disease 37:8, pages 2807-2826.
Crossref
Crossref
Fangyi Zhao, Bingjin Li, Wei Yang, Tongtong Ge & Ranji Cui. (2022)
Brain–immune
interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders
. Cell Proliferation 55:10.
Crossref
Crossref
Yan Zhang, Han Shi, Ge Yang, Yongfeng Yang, Wenqiang Li, Meng Song, Minglong Shao, Xi Su & Luxian Lv. (2021) Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia. Translational Psychiatry 11:1.
Crossref
Crossref
Maria A. Tikhonova, Tamara G. Amstislavskaya, Ying-Jui Ho, Anna A. Akopyan, Michael V. Tenditnik, Marina V. Ovsyukova, Alim A. Bashirzade, Nina I. Dubrovina & Lyubomir I. Aftanas. (2021) Neuroprotective Effects of Ceftriaxone Involve the Reduction of Aβ Burden and Neuroinflammatory Response in a Mouse Model of Alzheimer’s Disease. Frontiers in Neuroscience 15.
Crossref
Crossref
Diego Romero-Miguel, Marta Casquero-Veiga, Karina S MacDowell, Sonia Torres-Sanchez, José Antonio Garcia-Partida, Nicolás Lamanna-Rama, Ana Romero-Miranda, Esther Berrocoso, Juan C Leza, Manuel Desco & María Luisa Soto-Montenegro. (2021) A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders. International Journal of Neuropsychopharmacology 24:9, pages 734-748.
Crossref
Crossref
Ruqayya Afridi, Sihwan Seol, Hyo Jung Kang & Kyoungho Suk. (2021) Brain-immune interactions in neuropsychiatric disorders: Lessons from transcriptome studies for molecular targeting. Biochemical Pharmacology 188, pages 114532.
Crossref
Crossref
Diego Romero‐Miguel, Nicolás Lamanna‐Rama, Marta Casquero‐Veiga, Vanessa Gómez‐Rangel, Manuel Desco & María Luisa Soto‐Montenegro. (2020) Minocycline in neurodegenerative and psychiatric diseases: An update. European Journal of Neurology 28:3, pages 1056-1081.
Crossref
Crossref
Andrea Zemba Cilic, Mladen Zemba, Matija Cilic, Igor Balenovic, Sanja Strbe, Spomenko Ilic, Jaksa Vukojevic, Zoran Zoricic, Igor Filipcic, Antonio Kokot, Domagoj Drmic, Alenka Boban Blagaic, Ante Tvrdeic, Sven Seiwerth & Predrag Sikiric. (2021) Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling ‘positive-like’ symptoms of schizophrenia. Behavioural Brain Research 396, pages 112919.
Crossref
Crossref
Hemen S. Ved & Gaurav M. Doshi. (2020) A Review on Emerging Drug Targets in Treatment of Schizophrenia. Current Drug Targets 21:15, pages 1593-1605.
Crossref
Crossref
Rose Jeppesen, Rune H.B. Christensen, Emilie M.J. Pedersen, Merete Nordentoft, Carsten Hjorthøj, Ole Köhler-Forsberg & Michael E. Benros. (2020) Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis. Brain, Behavior, and Immunity 90, pages 364-380.
Crossref
Crossref
Santiago G. Lago, Jakub Tomasik, Geertje F. van Rees, Jordan M. Ramsey, Frieder Haenisch, Jason D. Cooper, Jantine A. Broek, Paula Suarez-Pinilla, Tillmann Ruland, Bonnie Auyeug, Olya Mikova, Nikolett Kabacs, Volker Arolt, Simon Baron-Cohen, Benedicto Crespo-Facorro & Sabine Bahn. (2018) Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. Molecular Psychiatry 25:10, pages 2355-2372.
Crossref
Crossref
Thomas RE Barnes, Richard Drake, Carol Paton, Stephen J Cooper, Bill Deakin, I Nicol Ferrier, Catherine J Gregory, Peter M Haddad, Oliver D Howes, Ian Jones, Eileen M Joyce, Shôn Lewis, Anne Lingford-Hughes, James H MacCabe, David Cunningham Owens, Maxine X Patel, Julia MA Sinclair, James M Stone, Peter S Talbot, Rachel Upthegrove, Angelika Wieck & Alison R Yung. (2019) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 34:1, pages 3-78.
Crossref
Crossref
Lulu Zhang, Hongbo Zheng, Rengrong Wu, Thomas R. Kosten, Xiang-Yang Zhang & Jingping Zhao. (2019) The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophrenia Research 212, pages 92-98.
Crossref
Crossref
Haythum O. Tayeb, Hussam A. Murad, Misbahuddin M. Rafeeq & Frank I. Tarazi. (2018) Pharmacotherapy of schizophrenia: toward a metabolomic-based approach. CNS Spectrums 24:03, pages 281-286.
Crossref
Crossref
Peng ZhengBenhua ZengMeiling LiuJianjun ChenJunxi PanYu HanYiyun LiuKe ChengChanjuan ZhouHaiyang WangXinyu ZhouSiwen GuiSeth W. PerryMa-Li Wong, Julio Licinio, Hong WeiPeng Xie. (2019) The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Science Advances 5:2.
Crossref
Crossref
Santiago G. Lago & Sabine Bahn. (2018) Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. ACS Chemical Neuroscience 10:1, pages 58-78.
Crossref
Crossref
Domenico De Berardis, Michele Fornaro, Annalisa Anastasia, Federica Vellante, Alessandro Valchera, Marilde Cavuto, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Laura Orsolini, Carmine Tomasetti, Gabriella Di Emidio, Giovanni Martinotti & Massimo Di Giannantonio. 2019. Treatment Resistance in Psychiatry. Treatment Resistance in Psychiatry
349
367
.
Reza Arezoomandan, Esmail Riahi & Abbas Haghparast. (2018) Minocycline increases firing rates of accumbal neurons and modifies the effects of morphine on neuronal activity. Addiction Biology 23:5, pages 1055-1066.
Crossref
Crossref
Fang Liu, Bingkui Zhang, Liqin Xie, Ye Ruan, XiuFeng Xu, Yong Zeng, Louis Messina, Jingping Zhao & Xiaoduo Fan. (2018) Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophrenia Research 199, pages 390-394.
Crossref
Crossref
Lulu Zhang, Hongbo Zheng, Rengrong Wu, Furong Zhu, Thomas R. Kosten, Xiang-Yang Zhang & Jingping Zhao. (2018) Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry 85, pages 69-76.
Crossref
Crossref
Deanna L. Kelly & Heidi J. Wehring. (2018) Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia. Psychiatric Annals 48:5, pages 224-231.
Crossref
Crossref
Maria Herrero-Zazo, Ruth Brauer, Fiona Gaughran, Louise M Howard, David Taylor & David J Barlow. (2017) Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study. Journal of Psychopharmacology 32:5, pages 559-568.
Crossref
Crossref
Geertje Frederique van Rees, Santiago Guillermo Lago, David Alan Cox, Jakub Tomasik, Nitin Rustogi, Karin Weigelt, Sureyya Ozcan, Jason Cooper, Hemmo Drexhage, F. Markus Leweke & Sabine Bahn. (2018) Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients. Brain, Behavior, and Immunity 67, pages 364-373.
Crossref
Crossref
Marco Solmi, Nicola Veronese, Nita Thapa, Silvia Facchini, Brendon Stubbs, Michele Fornaro, André F. Carvalho & Christoph U. Correll. (2017) Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums 22:5, pages 415-426.
Crossref
Crossref
Daniel Erny, Anna Lena Hrabě de Angelis & Marco Prinz. (2017) Communicating systems in the body: how microbiota and microglia cooperate. Immunology 150:1, pages 7-15.
Crossref
Crossref
M. Sheerin & A. Adejare. 2017. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
249
265
.
Hans O. Kalkman & Dominik Feuerbach. (2016) Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders. Cellular and Molecular Life Sciences 73:13, pages 2511-2530.
Crossref
Crossref
Seong Shim, Michael Shuman & Erica Duncan. (2016) An emerging role of cGMP in the treatment of schizophrenia: A review. Schizophrenia Research 170:1, pages 226-231.
Crossref
Crossref
Helen K. Smith, Cristiane Damas Gil, Sonia M. Oliani & Felicity N. E. Gavins. (2015) Targeting formyl peptide receptor 2 reduces leukocyte‐endothelial interactions in a murine model of stroke. The FASEB Journal 29:5, pages 2161-2171.
Crossref
Crossref